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Identification of genes affected by disease-associated rare chromosomal rearrangements has led to the cloning of several disease genes. Here
we have used a simple approach involving allele-specific RT-PCR-based detection of gene expression to identify a gene affected by a balanced
autosome;autosome translocation. We identified a transcribed SNP (tSNP), c.68G→A, present in a novel untranslated exon of the CLDN14 gene
in a male patient with mental retardation who had a balanced t(13;21) chromosomal translocation. We determined an allelic loss of expression of
the CLDN14 gene isoform at the 21q22.1 chromosomal breakpoint. Although additional work is necessary to explore a possible function of the
novel CLDN14 isoform in brain development and function and the potential pathogenic consequences of its disruption in this patient, the result
clearly demonstrates the utility of a tSNP-based detection of allelic loss of gene expression in studies involving chromosomal rearrangements.
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cloning approaches has proven to be one of the most powerful
tools in unraveling gene function. Autosomal dominant diseases
are normally caused by a defect in one of two copies of an
autosomal gene. Such defects lead to either haploinsufficiency
or a gain in gene function. Identification of causative autosomal
genes in diseases of a heterogeneous nature such as mental
retardation and autism has proven to be very difficult due to the
lack of large families for linkage analysis [1]. Furthermore,
phenotypic variability among small families, often consisting of
single sibships, precludes the pooling of families for linkage
analysis. Thus, progress in the identification of autosomal
mental retardation (MR) genes has been very limited [2–4].
Studies involving disease-associated rare chromosomal
rearrangements, such as balanced translocations, inversions,
and duplications, have been very productive in identifying the
causative genes [5,6]. However, mapping of the chromosomal
breakpoints is a labor-intensive and multistep process and
requires delineation of the critical chromosomal breakpoint⁎ Corresponding author. Fax: +1 864 388 1808.
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critical region [5–8]. In most of these cases, the causative genes
have been found to be physically disrupted by the chromosomal
breaks. However, in a number of cases, a long-range effect of
the chromosomal break on genes located at a distance has also
been identified [9]. Although productive, there are limitations in
the use of traditional approaches for detecting genes disrupted
or affected by a chromosomal break.
Real-time RT-PCR expression analysis to determine expres-
sion variations in genes affected by chromosomal rearrange-
ments has also been utilized in a limited number of studies [10].
However, this has not been a method of choice due to the wide
range of observed expression variability of reference and
experimental genes among test or control samples [11,12].
Allele-specific gene expression has been extensively utilized in
studies of gene silencing related to X inactivation and
imprinting studies [13–15]. Here we have used a transcribed
SNP (tSNP)-based RT-PCR approach and show its utility in the
identification of a gene affected by a chromosomal breakpoint
in a 19-year-old patient with a balanced t(13;21) (q22;q22.1)
translocation, mild MR (IQ 69), macrocephaly (OFC>98th
percentile), and aggressive behavior.
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clinical features in the patient, we mapped the 21q22.1 break-
point to an approximate 50-kb genomic region flanked by two
previously characterized genes, CLDN14 and SIM2 (cen–
CLDN14–21q breakpoint–SIM2–ter) using fluorescence in situ
hybridization (data not shown). It has been suggested that an
extra copy of SIM2 may be important for the pathogenesis of
Down syndrome, especially mental retardation (MIM 600892)
[16]. However, a role for the Down syndrome critical region
genes in specific Down syndrome phenotypes has been debated
[17]. The SIM2 gene mapped approximately 200 kb telomeric
to the breakpoint and was apparently not affected by the trans-
location breakpoint.
The CLDN14 gene comprises three exons spanning (tel→
cen) about 19.4 kb of genomic DNA. The first two exons of the
CLDN14 gene encode a 5′ untranslated region; exon 3 contains
the complete 720-bp open reading frame, encoding a 239-
amino-acid protein of the claudin gene family. An isoform of the
CLDN14 gene has been previously shown to be mutated in some
cases of nonsyndromic deafness (DFNB29) (MIM 605608) [18–
20]. No deafness was noted in the present patient.
To determine if one of the two genes or a new previously
unidentified expressed sequence is affected by the 21q break-
point in the patient, we performed computer-assisted sequence
analysis of the breakpoint critical region. A limited number of
EST sequences were identified within the breakpoint interval.
Further EST sequence analysis and analysis of the correspond-
ing mouse sequences led to identification of three novel 5′
untranslated exons and two new transcript isoforms of theFig. 1. A schematic representation of the 21q22.1 chromosomal breakpoint region in
transcription. The entire open reading frame of the CLDN14 gene is present in exon 3
the CLDN14 gene are shown. The respective GenBank accession numbers of the va
strand) and c.11C/A and c.63G/A in coding exon 3 (top strand), are indicated.CLDN14 gene (variants 3 and 4; Fig. 1). These findings also
complemented recently identified novel isoforms of the
CLDN14 gene [20]. Altogether, identification of novel
CLDN14 isoforms extended the 5′ end of the CLDN14 gene
further within the 21q breakpoint region and suggested a likely
physical disruption of the CLDN14 gene (Fig. 1) by the 21q22.1
breakpoint. We hypothesized that the chromosomal break at
21q22.1 should lead to a loss of expression of a copy of a
CLDN14 gene isoform located on the derivative chromosome
21.
To check for an effect of the 21q chromosomal break on the
expression of a novel CLDN14 isoform, we performed
quantitative RT-PCR analysis. However, results were incon-
clusive. Therefore, we devised an alternative approach to look
for the expression of the CLDN14 gene using allele-specific RT-
PCR. First, we identified a heterozygous nucleotide variation
(c.68G→A) in the novel untranslated exon 1a of the CLDN14
gene in the patient (Figs. 1 and 2A, top). We used this tSNP to
examine specifically the expression of one of the two isoforms
of the CLDN14 gene (Fig. 1, variant 3) that was predicted to be
disrupted by the translocation breakpoint. We performed allele-
specific RT-PCR analysis on total RNA extracted from the
patient’s EBV-transformed lymphoblasts as described pre-
viously [21]. First-strand synthesis was performed using the
SuperScript first-strand synthesis system for RT-PCR (Invitro-
gen). A cDNA amplicon was amplified using primers specific
for CLDN14 exon 1a (5′-TGGCTGGGCTGGGTGGTCTC-3′)
and exon 1b (5′-AGCGGCCATGAGCTGGTGTG-3′) in a
reaction volume of 25 μl that contained 10 μM each primer,the patient with the t(13;21) translocation. Arrows indicate the direction of the
. The novel alternative exons (1a, 1b, and 1c) and transcript variants/isoforms of
riants are in parentheses. Three tSNPs, c.68G/A in alternative exon 1a (bottom
Fig. 2. Detection of an allele-specific loss of CLDN14 gene expression in the patient with t(13;21). Automated sequence traces (antisense strand) showing the CLDN14
tSNP in (A) the patient and in (B) one of two control individuals. The exon 1a-specific amplicon was amplified using genomic DNA and the gel-purified products were
sequenced for both stands. The patient was heterozygous for c.68G/A (top). The corresponding RT-PCR product, amplified using exon 1a- and exon 1b-specific
primers, showed only the c.68G allele in the patient total RNA (A, bottom), but both alleles, c.68G and c.68A, in the control (B, bottom). The results show that both
copies of the gene are expressed in normal control individuals but only one copy of the gene is expressed in the patient.
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(Sigma) with 0.02 μM TaqStart antibody (Clontech). The RT-
PCR conditions included an initial denaturation at 95°C for
300 s, followed by 40 cycles of 95°C for 30 s, 69°C for 30 s, and
72°C for 30 s. The PCR product (140 bp) was gel purified and
both strands were sequenced using the DYEnamic ET Dye
Terminator Cycle Sequencing Kit (GE Healthcare) and the
automated MegaBACE 1000 DNA analysis system (GE
Healthcare). Sequences were analyzed using the DNASTAR
program (Madison, WI, USA). Sequence analysis revealed that
the patient’s cDNA carried only a “G” allele at nucleotide 68
(Fig. 2A). Taken together, the results indicate that only one copy
of CLDN14 was transcribed and suggested a loss of expression
of the second copy of CLDN14 located on the derivative
chromosome 21.
To exclude a possibility of an imprinting effect on the
CLDN14 gene expression that may have caused the monoallelic
expression of the CLDN14 gene in the patient, we analyzed
both genomic DNA and cDNA from two control individuals
who were also heterozygous for the c.68G/A variation (Fig. 2B)
and apparently carried two normal chromosomes 21. A normal
biallelic expression of the CLDN14 gene was determined in
both controls (Fig. 2B and data not shown). These findings
suggest that both copies of the CLDN14 gene are expressed in
the control individuals. Altogether, the results would point to
the loss of allele “A” in the patient being due to a disrupted copy
of the CLDN14 gene located on the derivative chromosome 21.
As expected, the results were further confirmed by ampli-
fying the cDNA products using a primer from exon 1b and exon
3 (variant 3). Furthermore, two additional tSNPs, c.11C/T and
c.63G/A, located in coding exon 3 were also examined in the
patient and in two controls (Fig. 1 and data not shown).
The functional significance of the CLDN14 isoforms
containing untranslated exons remains to be determined. Arole for the smaller CLDN14 isoform containing exon 1, exon 2,
and exon 3 in autosomal recessive deafness has been reported
[18–20]. The patient studied here reportedly has no deafness.
Although a likely role for one of these isoforms in human brain
function is predicted, the present data are not sufficient to draw
any such conclusion and would require additional functional
studies. Nonetheless, the method described here was clearly
able to show the utility of allele-specific RT-PCR in determining
the effect of the translocation breakpoint on the transcription of
one copy of the CLDN14 gene in the patient.
Polymorphic genomic markers and single-nucleotide poly-
morphic alterations have been extensively used in genotype
analysis using genomic DNA. SNPs as well as other
polymorphic markers have also been used extensively to infer
genomic deletions, in studies involving uniparental disomy and
loss of heterozygosity, and in imprinting studies [13,22,23]. The
approach described here utilizes the presence of a heterozygous
nucleotide alteration in transcribed regions to identify genes
affected by the translocation breakpoints.
In most autosomal dominant cases, a chromosomal
rearrangement would likely result in the loss of expression
of one copy of a gene either by physical disruption of the gene
or due to its presence in close vicinity of the breakpoint.
However, in the latter case, an overexpression of the gene due
to physical separation of a regulatory element by the
breakpoint cannot be excluded. Detection of such long-range
effects of the autosomal breakpoints on a gene(s) located at
some distance from the breakpoint remains problematic [24].
Utility of real-time expression analysis using quantitative RT-
PCR has also been very limited [10]. Thus, the tSNP-based
RT-PCR approach described here provides a quick and
efficient screening method to analyze a large number of
genes from the breakpoint critical regions or regions flanking
chromosomal breakpoints. A similar approach has been
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autosome translocations to examine spreading of X inactiva-
tion in the translocated segment of the autosomes [25]. The
approach can be easily adapted to determine quantitative
expression difference due to difference in copy number of the
gene utilizing any tSNP [26,27] via information available
through the SNP database (http://www.ncbi.nlm.nih.gov/). It is
important to note that this approach is increasingly feasible
because there are now over 5,000,000 SNPs available for
potential use for screening of genes and isoforms, and the
annotation of the genome map is very informative. The
candidate genes from the breakpoint regions could be easily
monitored for the presence of informative heterozygous tSNPs.
In the present study, we tested and provide a simple and
efficient approach for identifying genes affected by chromoso-
mal breakpoints. We have been applying this tSNP-based
approach to screen and identify genes affected by the
translocation breakpoint in other cases with chromosomal
rearrangements. We have successfully analyzed a candidate
gene in a female patient with a t(3;9) translocation. Furthermore,
we were able to screen genes present at a distance and flanking
the breakpoints in a patient with a t(2;11) translocation and
determined a normal biallelic expression. This suggests that the
approach can also be efficiently used to screen a number of
genes from the chromosomal breakpoint critical regions to
determine a long-range effect of the chromosomal break on the
gene expression when the breakpoint does not necessarily
disrupt a gene.
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